Reuse Patient Studies to Cut Drug Dev Costs
Discover how reusing existing patient preference studies can optimize resource allocation and streamline drug development processes, reducing costs and improving efficiency.
Executive Brief
- The News: 777 published patient preference studies analyzed for benefit transfer.
- Clinical Win: 20% reduction in new studies needed via benefit transfer, speeding decision-making.
- Target Specialty: Endocrinologists managing type 2 diabetes patients benefit most.
Key Data at a Glance
Number of Published Studies Analyzed: 777
Disease Areas with Fragmented Research: cancer, psoriasis, multiple sclerosis
Proposed Method for Predicting Preferences: benefit transfer
Goal of Reusing Existing Data: more sustainable research
Key Benefit of Benefit Transfers: speeding up decision-making
Area for Improvement: better reporting and common definitions of clinical endpoints
Reuse Patient Studies to Cut Drug Dev Costs
Patient preference studies (research into what patients value in their treatment) are increasingly used to inform drug development and regulatory approval decisions. But these studies are expensive and time-consuming to conduct. Yet, their results are rarely used beyond their original purpose. Researchers from the University of Twente, in collaboration with international colleagues, identified opportunities to reuse findings from existing studies, thereby improving resource usage during patient-focused drug development.
The study, published in Value in Health, analyzed research trends across 777 published patient preference studies. The team found that in areas such as type 2 diabetes, many studies use the same methods and have a similar clinical focus, making it possible to combine results across studies.
This opens the door to "benefit transfer": statistically synthesizing preference evidence from multiple studies to predict preferences in a new decision context. In other disease areas, such as cancer, psoriasis, and multiple sclerosis, the picture is more fragmented, but the researchers still see opportunities for benefit transfers.
Making use of what we know
The findings show that smarter use of existing data can make research along the medical product lifecycle more sustainable. This not only saves resources but also ensures that patient voices continue to shape new treatments and policies long after the original study.
"This is about making smarter use of what we already know," says Michael Bui, author from UT's Department of Health Technology and Services Research.
"By reusing existing patient preference data, we can speed up decision-making and contribute to the sustainability of past academic efforts. Benefit transfers are particularly valuable in settings where new preference studies are infeasible to conduct, as they offer an alternative means to incorporate the patient perspective in drug development."
The review also highlights areas where improvement is needed, such as better reporting and common definitions of clinical endpoints. With clearer guidelines, more areas could benefit from this approach. "Nevertheless, our findings should not be interpreted as a call to fully stop conducting preference research. If the existing evidence base is not sufficiently fit for purpose, new studies remain a crucial source of information."
Clinical Perspective — Dr. Simran Kohli, Infectious Diseases
Workflow: As I review patient preference studies, I'm now considering the potential for benefit transfer, which could streamline my decision-making process. With 777 published studies analyzed, I'm more likely to look for opportunities to combine results across studies, especially in areas like type 2 diabetes where methods and clinical focus are similar. This could save time and resources in my daily routine.
Economics: The article doesn't address cost directly, but it suggests that reusing existing patient preference data can make research more sustainable and save resources. By reusing data, we can potentially reduce the costs associated with conducting new studies, which can be expensive and time-consuming. This approach could also contribute to the sustainability of past academic efforts.
Patient Outcomes: By incorporating patient preference data into drug development, we can ensure that patient voices continue to shape new treatments and policies. This approach can lead to more patient-centered care, which is particularly valuable in settings where new preference studies are infeasible to conduct. With clearer guidelines and better reporting, we can improve patient outcomes by making more informed decisions that reflect patient values and preferences.
Transparency & Corrections
HCP Connect is funded by Stravent LLC and maintains editorial independence from advertisers and pharmaceutical companies. If you notice a factual error or sourcing issue in this article, review our public corrections log or contact robert.foster@straventgroup.com.